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First discovered in 1962, heat shock proteins (HSPs) are highly studied with about 35,500
publications on the subject to date. HSPs are highly conserved, function asmolecular chap-
erones for a large panel of “client” proteins and have strong cytoprotective properties.
Induced by many different stress signals, they promote cell survival in adverse conditions.
Therefore, their roles have been investigated in several conditions and pathologies where
HSPs accumulate, such as in cancer.Among the diversemammalianHSPs, somemembers
share several features that may qualify them as cancer biomarkers. This review focuses
mainly on three inducible HSPs: HSP27, HPS70, and HSP90. Our survey of recent literature
highlights some recurring weaknesses in studies of the HSPs, but also identiﬁes ﬁndings
that indicate that some HSPs have potential as cancer biomarkers for successful clinical
applications.
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INTRODUCTION
Heat shock proteins (HSPs) are important molecular players in
the cellular stress response (Macario and Conway de Macario,
2004). They can be divided into ﬁve superfamilies according to
their molecular weight: small HSPs [or HSPB family with the
recent ontology (Kampinga et al., 2009)], HSP40 (DNAJ ), HSP70
(HSPA), HSP90 (HSPC), and HSP110 (HSPH ). Two main func-
tions have been described for HSPs: ﬁrstly, they act as molecular
chaperones thereby playing a role in protein folding, aggrega-
tion, transport, and/or stabilization. Secondly, they prevent cell
death, for instance by preventing post-mitochondrial apoptosis in
caspase-dependent (e.g.,HSP27,HSP70, andHSP90) and/or inde-
pendent (e.g., HSP70) pathways (Gallucci and Matzinger, 2001).
HSPs were ﬁrst discovered in Drosophila melanogaster as a set
of proteins whose expression was induced by heat shock. They
are highly conserved proteins, present in the three domains of
life: archaea, bacteria, and eukaryotes (Macario and Conway de
Macario, 2004). HSPs are now also called stress proteins since their
expression was found to be induced in response to a wide variety
of physiological and environmental insults allowing cells to sur-
vive to otherwise lethal conditions. Stressors can be physical and
chemical insults such as radiation, including ultraviolet light and
magnetic ﬁelds, compression, shearing and stretching, hypoxia,
pH shift, nutrient deprivation, or exposure to reactive oxygen
species, alcohols, or metals. They also include biological insults
such as fever, cold, infection, inﬂammation, diseases including
cancer, cardiac diseases, and neurodegenerative disorders. Cel-
lular stress can also be triggered by treatments with anticancer
drugs or antibiotics (Ciocca and Calderwood, 2005; Macario and
Conway de Macario, 2005; Garrido et al., 2006; Jego et al., 2010;
Willis and Patterson, 2010;Macario et al., 2011).HSPs are reported
to be overexpressed in several pathologies. As such, members of
the large HSP family are studied widely as they may represent
interesting biomarker candidates. Chaperones such as HSP70 and
HSP90 tend to be team-players, acting together with other chaper-
ones and cochaperones (Macario and Conway de Macario, 2005).
Chaperone–cochaperone complexes such as HSP70, HSP40, and
nucleotide-exchange factor are able to help nascent polypeptide
chains to fold properly, refold damaged molecules, and can also
direct proteins to a protein-degrading mechanism such as the
ubiquitin–proteasome system (Lanneau et al., 2010). Each HSP is
localized in one or a set of speciﬁc compartment(s). For instance,
HSP70 and HSP90 can be present in the cytosol and the nucleus,
whereas HSP60 is found in mitochondria (see Figure 1) and grp78
(Bip, or HSPA5) in the endoplasmic reticulum. Microorganisms
may be another source of detectableHSPs. Indeed,humansmay be
considered as a “superorganism,” colonized by around a thousand
different species of microorganisms. These are mostly bacterial
cells present in the intestinal tract. These bacterial cells outnum-
ber our cells by at least a factor of 10, (the total number of cells
comprising the adult human body, both native and foreign, being
estimated to ∼1014) and their genes outnumber our own by a
factor of 100. These HSPs from microorganisms often induce a
proinﬂammatory response. Thus, when measuring anti-HSP lev-
els, especially against a conserved constitutive chaperone such as
HSP60, it is important to consider the protein may originate from
microorganisms. In this review we will focus on HSP60 and the
three most inducible HSPs: HSP27, HSP70, and HSP90.
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FIGURE 1 | Stressors of physical, chemical, or biological origin, as well
as diseases such as cancer can induce the accumulation of heat shock
proteins necessary for the survival of cancer cells.This scheme
illustrates the main localizations of HSP60, present in the mitochondria, and
the three inducible cytosolic/nuclear HSPs: HSP27, HSP70 (also found in
the cell membrane), and HSP90.
EXTRACELLULAR HSPs: CIRCULATING AND MEMBRANE-BOUND HSPs
Due to their lackof a transmembranedomain,HSPs are considered
intracellular soluble proteins (Gallucci and Matzinger, 2001) that
can be induced by a wide panel of stress signals and have strong
protective properties. However, HSPs such as HSP27, HSP60,
HSC70, HSP70, and HSP90 can also be found in the extracel-
lular environment where their role is believed to be immunogenic
(Schmitt et al., 2007). How HSPs are found in the extracellular
medium is still a debated issue. HSPs lack the consensus signal
for secretion via the classical Golgi pathway. The ﬁrst hypothesis
was attributed to spontaneous cell death leading to HSP extrava-
sation (Basu et al., 2000). However, it was found that undamaged,
live cells released HSP70 by an active non-classical secretory path-
way that was not affected by ER Golgi system inhibitors such as
brefeldin A (Hightower and Guidon, 1989; Hunter-Lavin et al.,
2004). Thus, active release of HSP70 might occur through one
or more alternative mechanisms (Nickel and Seedorf, 2008). Dif-
ferent pathways have also been proposed for HSP70 release: a
lysosome–endosome pathway (Mambula and Calderwood, 2006)
or a release by secretory-like granules (Evdonin et al., 2006), but
the bulk of the evidence points to an insertion of HSP70 oligomers
into the lipid bilayer of export vesicles. These oligomers formATP-
dependent ion channels, leaving only a small C-terminal region of
the protein outside (Vega et al., 2008). Thus, several mechanisms
have been proposed to account for the release of these HSPs into
bioﬂuids, however the question remains unresolved (Didelot et al.,
2007; Joly et al., 2010; De Maio, 2011).
SomeHSPs can also be foundon the cell surface, such asHSP70.
This has been widely reported in a variety of conditions, especially
for cancer and immune cells (De Maio, 2011). For cell surface
display to occur, a high intracellular HSP level is thought to be
necessary. For display of HSP70, for example, only about 10% of
the intracellular HSP70 is translocated to the cell membrane. The
high speciﬁcity of HSP70 and HSC70 for membranes seems to
be related to membrane ﬂuidity and thus to lipid composition
of the bilayer, due to afﬁnity for phosphatidylserine and choles-
terol (Arispe et al., 2004; Schilling et al., 2009). Presence of HSP70
in the membranes was stable even when treated with non-ionic
detergent, suggesting its insertion into lipid rafts (Hunter-Lavin
et al., 2004; Vega et al., 2008). In contrast to intracellular HSPs
that mainly play a cytoprotective role, some extracellular HSPs
such asHSP27 andHSP70,have immunogenic properties (Didelot
et al., 2007) and may induce either a pro- or an anti-inﬂammatory
response. Because cellmembranes can contain a certain amount of
HSPs, exosomes, and other vesicles derived from these membranes
also harbor HSPs on their membranes. For example, membrane-
bound HSP70 in vesicles were shown to activate macrophages
(Vega et al.,2008).Wehave recently shown that tumor-derived exo-
somes harboring HSP70 in the membrane triggered STAT3 acti-
vation in myeloid-derived suppressive cells, leading to tolerance of
the immune system to the tumor cells (Chalmin et al., 2010). Such
tumor-derived exosomes displaying HSPs may provide interesting
options for cancer detection and need to be further explored.
BIOMARKERS
Auseful biomarker needs to fulﬁll several criteria (Seigneuric et al.,
2010). It should ideally be at least: (i) overexpressed and positively
associated with the pathology of interest in order to identify cases,
(ii) speciﬁc to the pathology of interest, (iii) relatively easy to mea-
sure, ideally by non-invasive assays, and (iv) induced as early as
possible to enable early detection.
The most widely used techniques for the investigation of extra-
cellularHSPs as cancer biomarkers have been: immunohistochem-
ical (IHC) stainings to detect the presence of a given HSP from a
biopsy, tissue microarrays (TMA),western blot (WB) analysis, and
enzyme-linked immunosorbent assay (ELISA), which allows HSP
levels to be quantiﬁed down to a few nanograms per milliliter, but
requires labels that may denature the protein of interest.
HSP27
HSP27 belongs to the small heat shock protein family. Its struc-
ture and function are thought to bemodulated byphosphorylation
mediated by MAPK2. Intracellular HSP27 plays an anti-apoptotic
role through interaction with Bid or cytochrome c (Bruey et al.,
2000) and also has a main role as a chaperone, preventing the
aggregation of misfolded proteins. As such,HSP27 may contribute
to the pathogenesis of human diseases such as cancer, autoim-
mune diseases, neurological disorders (e.g., Alzheimer’s disease),
and cardiovascular diseases, where HSP27 has been investigated as
a biomarker for myocardial ischemia (Ghayour-Mobarhan et al.,
2011). In the context of oncology, HSP27 has been detected in
both the intracellular and extracellular environment. An increased
level of HSP27 has been reported in ovarian cancer, and more fre-
quently in prostate and breast cancers. Overexpression of HSP27
was found to correlate with poor prognosis for patients with these
diseases (Langdon et al., 1995; Calderwood, 2010; Khalil et al.,
2011). HSP27 was also reported to contribute to invasion and
metastasis (Xu et al., 2006), suggesting that HSP27 could be a
biomarker for the diagnosis of cancer (Lee et al., 2005).
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In a study of biopsy samples from prostate cancer patients,
expression of intracellular HSP27 was reported using IHC
stainings (see Table 1). It was observed that HSP27 expres-
sion in prostate cancer tissue was up-regulated compared to
the controls (Miyake et al., 2006). Similar qualitative results
were also obtained in breast cancer (Rui et al., 2003). HSP27
levels in serum and/or tumor microenvironment were deter-
mined by ELISA. Serum levels of HSP27 were signiﬁcantly higher
(P< 0.001) in breast cancer patients (1,038.38± 155.37 pg/mL;
n = 32) compared to healthy controls (256.29± 54.01 pg/mL;
n = 26). Interestingly, HSP27 released by patients’ tumor cells
were signiﬁcantly greater (P< 0.0001) than that measured
in the serum with 24,220± 4,796 pg/106 cells/mL (n = 7) and
1,459± 471 pg/106 cells/mL (n = 7), respectively.Another studyof
breast cancer patients showed that HSP27 levels in the interstitial
ﬂuid isolated from primary breast tumor could be extremely high:
2,615,428± 566,442 pg/mL; (n = 7). This concentrationwasmore
than: 2,500-fold higher than that detected in patients’ serum,more
than 100-fold that of patients’ breast tumor culture supernatants,
and more than 25-fold higher than the HSP27 level detected in the
normal breast tissue interstitial ﬂuid (103,600± 35,702 pg/mL).
Although the number of patients was very small (n = 3), this pre-
liminary study suggests highly elevated levels of soluble HSP27
in the human primary breast tumor microenvironment (Banerjee
et al., 2011). It would be interesting to conﬁrm this ﬁnding with a
larger cohort of patients.
HSP60
HSP60, initially called chaperonin, was one of the ﬁrst chaper-
ones studied. It plays an essential role in the transport and folding
of mitochondrial proteins, and is reported to be associated with
different cancers (see Table 2).
Clinical data from patients with localized and locally advanced
prostate cancer showed an association between IHC expres-
sion of HSP60 and tumor progression. HSP60 expression was
also reported to be highly associated with androgen indepen-
dence in the group of locally advanced cancers with andro-
gen ablation (Castilla et al., 2010). The intensity and extent of
immunoreactivity of HSP60, estimated by TMA analyses, signif-
icantly predicted biochemical recurrence. It was shown that, for
patients with intense HSP60 staining in biopsy, recurrence-free
survival was shorter than in those with weak expression (Glaess-
gen et al., 2008). A study performed in human prostate cancers
indicates that HSP60 expression assessed via IHC increases in
both early and advanced prostate cancer when compared with
non-neoplastic prostatic epithelium (Cornford et al., 2000). The
semi-quantitative evaluation of HSPs expression level showed
no association with Gleason score neither for the early nor for
the advanced cancers. Data from WB analyses of whole lysates
in prostate cancer cell lines was consistent with data from tis-
sue specimens. Indeed, each of the malignant cell lines tested
showed an increased HSP60 expression but no identiﬁable differ-
ence in relative expression between stage or grade of the individual
cancers.
The prognostic signiﬁcance of HSP60 in cervical cancer caused
was assessed by 2-DE, semi-quantitative reverse transcriptase poly-
merase chain reaction (RT-PCR) and WB analyses (Hwang et al.,
2009). The results from 2-DE proteomics, conﬁrmed by WB
analyses (P< 0.05), suggest that HSP60 may be involved in the
development of cervical cancer.
Autoantibodies may be an excellent tool for the early diagno-
sis of cancer. Many studies have investigated the tumor-associated
autoimmune response to identify new early diagnostic markers.
In breast cancer patients, ELISA experiments showed the presence
Table 1 | Selection of recent publications assessing HSP27 as a biomarker in cancers.
Sample type Cancer type Total number of samples Assay Finding/claim (References)
Biopsy Prostate 97 patients IHC HSP27 expression level was signiﬁcantly associated with Gleason score,
but not with studied factors before radical prostatectomy (Miyake et al.,
2006)
Tissue Prostate 120 patients; 60 controls IHC The level of HSP27 expression was correlated with their Gleason grade and
associated with poor clinical outcome (Cornford et al., 2000)
Tissue Bladder 42 patients; 10 controls IHC No correlation between HSP27 expression and grade was found (Lebret
et al., 2003)
Tissue HCC 38 patients IHC, DI HSP27 expression increased with the progression of hepatitis B virus-
related HCC (Lim et al., 2005)
Tissue Prostate 193 patients IHC HSP27 expression signiﬁcantly associated with several conventional prog-
nostic factors (Miyake et al., 2010)
Serum Breast 32 patients; 26 controls ELISA Higher levels of HSP27 released in the tumor microenvironment compared
to serum levels of cancer patients (Banerjee et al., 2011)
Serum Breast 76 patients; 54 controls 2-DE; MALDI–
TOF–MS
HSP27 was up-regulated in the serum of breast cancer patients (Rui et al.,
2003)
Serum Ovarian 158 patients; 80 controls ELISA The mean concentration of anti-HSP27 antibodies was signiﬁcantly higher
than in the control group (Olejek et al., 2009)
Techniques are: 2-DE, two-dimensional gel electrophoresis; DI, dot immunoblot; ELISA, enzyme-linked immunosorbent assay, IHC, immunohistochemical analyses;
MALDI–TOF–MS, matrix-assisted laser desorption/ionization – time-of-ﬂight – mass spectrometry. HCC stands for hepatocellular carcinoma.
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of autoantibodies against HSP60 and the level of serum HSP60
antibodies was found to be dependent on the cancer grade. Inter-
estingly, high grade tumors showed a more elevated level of HSP60
autoantibodies compared to low-grade tumors.HSP60mRNA lev-
els were signiﬁcantly higher in primary breast cancer compared
to healthy breast tissues. Using IHC, it was found that HSP60
expression increased from normal to invasive tissues (Desmetz
et al., 2008). Based on a serological proteomics-based approach, a
humoral immune response in patientswith breast cancer related to
HSP60 was found (Hamrita et al., 2008). These authors looked for
the presence of IgG antibodies against MCF-7 cell line proteins.
They found a higher level for the molecular chaperone HSP60.
In line with these results, IHC analyses performed on breast can-
cer biopsies showed increased expression of HSP60 in tumors of
advanced clinical stage when compared with earlier stage carcino-
mas (Isidoro et al., 2005). These results support the fact thatHSP60
overexpression during the initial stages of breast carcinogenesis
may be clinically relevant for the early diagnosis of breast can-
cer. HSP60 was also identiﬁed by antibodies in sera from patients
with chronic hepatitis, liver cirrhosis, or hepatocellular carcinoma.
However, HSP60 antibodies in precancer conditions were not a
useful candidate as a biomarker for pancreatic cancer. Further
investigations should be performed to determine the quantitative
changes of this chaperone protein associated with early events
leading to tumorigenesis (Looi et al., 2008). In colorectal car-
cinoma, the elevated expression of HSP60 showed a signiﬁcant
association with tumor differentiation, and may indicate a worse
prognosis (Mori et al., 2005).
The correlationof HSP60 expressionwith tumor growth and/or
progression makes this chaperone protein a potential biomarker.
However, more efforts should be devoted to quantitative analy-
ses of HSP60 expression to resolve existing contradictory ﬁndings
concerning its association with a good or a poor prognosis (see
Table 2).
HSP70
TheHSP70 superfamily consists of at least 13members (Kampinga
et al., 2009). Inducible HSP70 (HSPA1A or HSP72), an exten-
sively studied, powerful ATP-dependent chaperone with key anti-
apoptotic properties (Garrido et al., 2006; Didelot et al., 2007;
Table 2 | Selection of recent publications assessing HSP60 as a biomarker in cancers.
Sample type Cancer type Total number of samples Assay Finding/claim (References)
Biopsy Prostate 107 patients WB; IHC HSP60 is overexpressed in tumors and strongly associated
with prognostic clinical parameters (Castilla et al., 2010)
Tissue Cervical 20 patients; 20 controls 2-DE; RT-PCR;
WB
Increased HSP60 expression (Hwang et al., 2009)
Tissue Prostate 289 patients IHC; TMA HSP60 overexpression was correlated with both biochem-
ical recurrence and Gleason score (Glaessgen et al., 2008)
Tissue Bladder 42 patients; 10 controls IHC HSP60 low expression levels correlated with higher tumor
stage. Loss of HSP60 expression was correlated with
tumor inﬁltration (Lebret et al., 2003)
Tissue Breast 149 patients IHC; TMA No association was found between HSP60 and prognosis
(Sebastiani et al., 2006)
Tissue Colorectal 44 patients cDNA
microarray;
IHC
A signiﬁcant association of HSP60 with tumor differentia-
tion and pT stage was observed (Mori et al., 2005)
Tissue, cell line Prostate 120 patients; 60 controls IHC;WB No correlationwas found between levels of HSP60 expres-
sion and phenotypic behavior of individual primary prosta-
tic cancers (Cornford et al., 2000)
Tissue Breast 101 patients; 13 controls WB; IHC Increased expression of HSP60 compared with controls.
HSP60 correlated with patient overall survival (Isidoro
et al., 2005)
Tissue HCC 38 patients IHC, DI Expression of HSP60 decreased during hepatocarcinogen-
esis (Lim et al., 2005)
Serum, tissue,
cell line
Breast; ovarian; prostate;
ductal carcinoma
147 patients; 93 controls ELISA; 2-DE;
WB; RT-PCR;
IHC
HSP60 was overexpressed during the ﬁrst steps of breast
carcinogenesis (Desmetz et al., 2008)
Serum cell line Breast 40 patients; 42 controls IHC; MALDI–
TOF–MS;
2-DE
Signiﬁcantly higher level of autoantibodies against HSP60
in breast cancer patient sera (Hamrita et al., 2008)
Techniques are: 2-DE, two-dimensional gel electrophoresis; DI, dot immunoblot; ELISA, enzyme-linked immunosorbent assay; IHC, immunohistochemical analyses;
MALDI–TOF–MS, matrix-assisted laser desorption/ionization – time-of-ﬂight – mass spectrometry; RT-PCR, reverse transcription polymerase chain reaction; TMA,
tissue microarray; WB, western blot.
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Seigneuric et al., 2011). HSP70 could be an interesting biomarker
because its overexpression in serum is associated with many
cancers. However, these studies are mostly qualitative. HSP70
is considered to be the most universally stress inducible HSP
(Suzuki et al., 2006) with reported inductions of over 200-fold
(Modi et al., 2007). A few clinical articles provide quantitative
data on HSP70 expression based on ELISA tests (see Table 3).
The relatively large case–control study nested in the Japan Col-
laborative Cohort Study for Evaluation of Cancer Risk (Suzuki
et al., 2006) reports HSP70 levels in the serum of lung cancer
patients in comparison with the C-reactive protein (CRP). The
data indicate mean levels of 2.41 ng/mL (n = 189) for cases ver-
sus 2.01 ng/mL (n = 377) for controls. This is to be compared
to smaller differences in the CRP levels: 0.92 ng/mL (n = 209)
versus 0.81 ng/mL (n = 425) respectively (Suzuki et al., 2006).
In colorectal cancer, the difference in serum levels of HSP70
between patients who survived (1.51 ng/mL, n = 95) compared
to patients who did not survive (1.84 ng/mL, n = 84) was reported
to be signiﬁcant (P= 0.014; Kocsis et al., 2010). ELISA-determined
concentrations of serum HSP70 autoantibody were reported
to be signiﬁcantly higher in esophageal squamous cell carci-
noma (ESCC) patients (0.412mg/mL, n = 16) than for patients
with gastric cancer (0.236mg/mL, n = 17, P < 0.001), colon can-
cer (0.231mg/mL, n = 19, P< 0.001), or healthy individuals
(0.207mg/mL, n = 13, P< 0.001; Fujita et al., 2008). Albeit lim-
ited in the number of patients and controls, this study suggests the
presence of autoantibody against HSP70 in the serum of ESCC
patients.
HSP90
HSP90 is an ATP-dependent chaperone that has been highly stud-
ied for anticancer therapy (Kamal et al., 2003; Solit and Chiosis,
2008; Jego et al., 2010) with targeted inhibitors being tested in
clinical trials in phase II/III. HSP90 ensures the quality control
of many proteins involved in cell-signaling pathways. It is also
essential for the stability and function of many oncogenic client
proteins (Taipale et al., 2010). Its expression in malignant cells
is reported to be high and constitutive, suggesting a crucial role
in survival and growth of cancer cells (Whitesell and Lindquist,
2005). Studies have investigated the potential prognostic value of
HSP90 in different cancers as shown in Table 4. In invasive breast
cancers, immunohistochemical analyses showed that HSP90 was
abundantly expressed in all tumor samples included in the study
(Song et al., 2010). A trend toward correlation (P = 0.062) was
identiﬁed between HSP90 expression and diminished relapse-free
survival (RFS) in the triple negative subtype (HER-, ER-, PR-).
In patients with HER+ (tumors HER2-clustered), the coexpres-
sion of HSP90 and PI3K-p110 (or loss of PTEN) predicted a
signiﬁcantly decreased RFS. In line with these results, it was sug-
gested that HSP90 overexpression in malignant breast cancer was
associated with decreased survival (Pick et al., 2007). Concerning
hepatocellular carcinoma, Lim et al. (2005) suggested that HSP90
expression increases along with the progression of hepatocarcino-
genesis. In fact, HSP90 expression showed a strong correlation
with prognostic factors of hepatocellular carcinoma, being associ-
ated with vascular invasion and metastasis. Similar ﬁndings were
observed in bladder cancer, where HSP90 level was correlated with
Table 3 | Selection of recent publications assessing HSP70 as a biomarker in cancers.
Sample type Cancer type Total number of samples Assay Finding/claim (References)
Biopsy HCC 176 patients IHC A panel of HSP70+glypican 3+glutamine synthetase proved
useful to detect well-differentiated HCC in biopsy (DiTommaso
et al., 2009)
Tissue Bladder 42 patients; 10 controls IHC No correlation was found with tumor grade, disease stage, and
patient outcome (Lebret et al., 2003)
Tissue Prostate 193 patients IHC Signiﬁcant association with either no or limited prognostic
parameters (Miyake et al., 2010)
Tissue Prostate 120 patients; 60 controls IHC No correlation was found between levels of HSP70 expression
and phenotypic behavior of individual primary prostatic cancers
(Cornford et al., 2000)
Tissue HCC 38 patients IHC, DI Positive correlation between HSP70 expression and prognostic
factors of hepatitis B virus-related HCC (Lim et al., 2005)
Serum Lung 189 patients; 377 controls ELISA High levels of serumHSP70might be associatedwith increased
risk of lung cancer among Japanese males (Suzuki et al., 2006)
Serum ESCC 16 patients; 13 controls ELISA; 2-DE;WB; MALDI–
TOF–MS, IHC
Concentrations of serum HSP70 autoantibody were signiﬁ-
cantly higher for patients with ESCC than for patients with
gastric or colon cancer or healthy individuals (Fujita et al., 2008)
Serum Colorectal 179 patients ELISA Serum level of soluble HSP70 may be a stage-independent
prognostic marker in colorectal cancer without distant metas-
tasis (Kocsis et al., 2010)
Techniques are: 2-DE, two-dimensional gel electrophoresis; ELISA, enzyme-linked immunosorbent assay; IHC, immunohistochemical analyses; MALDI–TOF–MS,
matrix-assisted laser desorption/ionization – time-of-ﬂight – mass spectrometry; DI, dot immunoblot;WB, western blot. ESCC, esophageal squamous cell carcinoma;
HCC, hepatocellular carcinoma.
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high grade tumor (Lebret et al., 2003). In studies on ovarian can-
cer, HSP90 expression was associated with higher stages, and so
may be a good indicator of aggressiveness when associated with
other HSPs (Elpek et al., 2003).
HSPs AS BIOMARKERS: HEADING FOR GOLD (STANDARDS)?
The ever increasing body of data dealing with HSPs reﬂects their
potential as both therapeutic targets and as biomarkers. We have
highlighted only some of the many interesting points, and identi-
ﬁed some pitfalls that are recurrent in many research ﬁelds (Ioan-
nidis, 2005; Mischak et al., 2010), and which should be addressed
to clarify future work concerning HSP detection.
For the validation of most results presented here, it is crucial
that large-scale studies be performed to conﬁrm these ﬁndings
(Ioannidis, 2005; Mischak et al., 2010). This review of recent
research articles on HSP detection in cancer reveals that the most
frequently used techniques are essentially qualitative. Overall, IHC
staining seems the most frequently used, regardless of the HSP of
interest. The two main disadvantages of IHC staining are that the
results are qualitative and subjective, like any image analysis. ELISA
tests should be favored to provide more objective, quantitative
data.
How speciﬁc are HSPs as biomarkers in cancer? HSPs are key
proteins that tend to be overexpressed in response to a large
panel of stressors. They are thus by deﬁnition not speciﬁc to
cancer. However, it is shown that HSPs are necessary for can-
cer cell survival, making cancer cells in fact addicted to these
cytoprotective chaperones. As a consequence, cancer cells express
high levels of HSPs compared to normal cells, and need them
for survival. It is clear that no single biomarker will be sufﬁcient
to detect cancer, its relapse or monitor a treatment (Seigneuric
et al., 2010). An alternative, then, is to combine different bio-
markers on the same level, (e.g., at the protein level) as exem-
pliﬁed by DNA microarrays and “omics” in general (Seigneuric
et al., 2009). Another way to deal with the inherent lack of speci-
ﬁcity of a single protein is to combine it with biomarkers from
Table 4 | Selection of recent publications assessing HSP90 as a biomarker in cancers.
Sample type Cancer type Total number of samples Assay Finding/claim (References)
Tissue Bladder 42 patients; 10 controls IHC HSP90 expression levels correlated with tumor inﬁltration (Lebret et al., 2003)
Tissue HCC 38 patients IHC; DI Positive correlation between HSP90 expression and prognostic factors of hepati-
tis B virus-related HCC (Lim et al., 2005)
Tissue Breast 212 patients IHC Expression of HSP90 was associated with 5-year relapse-free survival (RFS).
Coexpression of HSP90 and PI3K or expression of HSP90 along with PTEN
loss demonstrated prognostic signiﬁcance in terms of RFS in patients with
HER2-positive cancers, but not with HER2-negative cancer (Song et al., 2010)
Tissue RCC 153 patients IHC HSP90 was expressed in most RCC specimens. No signiﬁcant association with
conventional diagnostic factors (Sakai et al., 2009)
Tissue Prostate 193 patients IHC No signiﬁcant association of HSP90 expression levels with conventional diagnos-
tic factors (Miyake et al., 2010)
Tissue Ovarian 52 patients IHC HSP90 expression was associated with higher stages but did not correlate with
prognosis (Elpek et al., 2003)
Tissue cell line Breast 655 patients IHC;WB High HSP90 expression was associated with decreased survival in primary breast
cancer (Pick et al., 2007)
Techniques are: IHC, immunohistochemical analyses; DI, dot immunoblot; WB, western blot. HCC, hepatocellular carcinoma; RCC, renal cell carcinoma.
FIGURE 2 | Peripheral blood is a biological fluid of high interest for HSP
detection in oncology since its composition besides red blood cells or
RBCs is reported to include, circulating HSP antibodies and
autoantibodies, HSP27, HSP70, and HSP90, as well as tumor-derived
exosomes expressing HSP70 at the membrane.The presence of circulating
tumor cells expressing HSP70 at their membrane remains to be
demonstrated but may be complementary to the EpCAM biomarker, which is
currently in clinical trials.
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other levels (see Figure 2). For instance, HSP expression at the
protein level could be integrated with the measurement of tumor-
derived exosomes expressingHSP70 in themembrane. Circulating
tumor cells (CTCs) represent another very interesting level. Crit-
ical to embryogenesis, cancer cells are thought to undergo an
epithelial-to-mesenchymal transition (EMT) during carcinogen-
esis, contributing to invasion and metastasis (Thiery, 2002; Thiery
et al., 2009). Indeed, altered cell–cell and cell–extracellular inter-
actions would enable: (i) the release of epithelial cells, or the“seed”
(Fidler, 2003) from the surrounding tissue, (e.g., primary tumor),
(ii) entering the circulation (intravasation), (iii) exiting the cir-
culation (extravasation), (iv) the colonization of distant organs
(Fidler, 2003). Current clinical investigations into the detection
of CTCs are based on the cell receptor EpCAM (Seigneuric et al.,
2010). However, EpCAM expression is supposed to decrease dur-
ing the circulation of CTCs in peripheral blood (or lymph), as
reported with ﬂow cytometry experiments (Rao et al., 2005).
This may lead to suboptimal detection of CTCs. The process
of EMT is well documented in cell lines and mice experiments,
but its clinical relevance remains debated (Ledford, 2011). In
contrast to normal cells, epithelial cancer cells circulating in a
liquid environment should have increased levels of membrane
HSP. Although this hypothesis remains to be tested, it would rep-
resent an interesting means to robustly detect CTCs based on
HSPs expression at the cell membrane. HSP70 is a strong can-
didate as various cancer cell lines express a fragment of HSP70
at their membrane that can be detected by an antibody (Stangl
et al., 2011). This is of high interest for cancer detection, as it
enables a means of characterization by ﬂow cytometry and ELISA
tests.
Heat shock proteins are essential proteins that are highly con-
served, but their expression levels between individuals is reported
to differ widely for HSP60 (Shamaei-Tousi et al., 2007), HSP70
(Modi et al., 2007), and/or HSP90 (Ramanathan et al., 2010). The
problem of this intrinsic variability in HSP expression may be
circumvented by using time series, assessing HSPs with longitu-
dinal data by following-up every single patient as a function of
time. In order to compare HSP levels between patients, adjust-
ing for age, gender, and ethnicity may be necessary. The role
of circulating HSP70 and/or HSP70 antibodies in the periph-
eral circulation in the context of aging is interesting (Pockley
et al., 1998). Reported ranges of HSP70 expression largely differ.
Indeed, discrepancies up to a few orders of magnitude, vary-
ing from a few ng/mL (Terry et al., 2006) to values 10 to a
100 times higher were reported (Rea et al., 2001; Njemini et al.,
2005), possibly due to ELISA matrix defects (Njemini et al.,
2005). However, the serum concentration of HSP70 is reported
to decrease with age (Rea et al., 2001; Macario and Conway de
Macario, 2005; Terry et al., 2006; Njemini et al., 2011) as is serum
HSP60 (Macario and Conway de Macario, 2005). The gender
issue should be also addressed. For instance, a 3.5 times higher
expression of circulating HSP60 was found in women’s periph-
eral blood compared to men (Macario and Conway de Macario,
2005). In addition, HSP70 serum concentrations in women were
about twice those in men (Pockley et al., 1998). The study of
Suzuki et al. (2006) reported differences in serum HSP70 levels
in cancer patients. The authors reported 2.46 ng/mL (n = 146)
in male versus 2.25 ng/mL (n = 43) in females. For healthy con-
trols however, serum HSP70 levels were quite similar: 2.00 ng/mL
(n = 285) and 2.06 ng/mL (n = 92) respectively (Suzuki et al.,
2006).
For an HSP to qualify as a cancer biomarker, its expression
levelmust be compared to gold standards or to commonly assessed
biomolecules.A circulatingHSP should be compared to other pro-
teins such as CRP, a systemic and non-speciﬁc marker of chronic
inﬂammation (Chaturvedi et al., 2010) used daily in practice, or
CA 15-3 (cancer antigen 15-3) or CA125 (cancer antigen 125),
which are widely used biomarkers for breast (Duffy, 2006) and
ovarian cancer (Petricoin et al., 2002), respectively.
CONCLUDING REMARKS
Research studies in cancer detection rely heavily on the identiﬁ-
cation of proteins, but how many proteins are in fact uniquely
expressed by cancer but not normal cells? Presumably, their pro-
teomes are shared at least to some extent, thus favoringquantitative
rather than qualitative techniques to reveal subtle differences in
expression levels currently found in the pico- to sub-nanomolar
range (Krueger, 2006). It is likely that HSPs will not discern differ-
ent cancer types. However, thismay be seen as themajor advantage
of HSPs: a potentially universal family of cancer biomarkers.
Since the data amassed during the past half century is essentially
qualitative, it is too early to suggest which HSP or combination of
HSPs may show promise in the future. Yet, even though many
studies focus on HSP60, we suggest focusing rather on inducible
HSPs that are seldom present in non-stressed normal cells. Among
these, HSP70 seems to be particularly interesting as it is the most
abundant inducible HSP in cancer cells and is also present in
the membrane of cancer cells but not in non-transformed cells.
In contrast to the common strategy relying on the combination
of several cancer biomarkers (Fung et al., 2007; Seigneuric et al.,
2009, 2010), HSP70 could allow a detection at different levels: cir-
culating protein, tumor-derived exosomes, and CTCs. Of course,
these assays need to be optimized and standardized. Furthermore,
their sensitivity and speciﬁcity should be addressed. As we recently
have shown, another interesting inducible HSP may be HSP110
whose expression can be used for the diagnosis of colon can-
cer patients presenting micro-satellite instability (Dorard et al.,
2011).
Because many HSP studies utilize a small number of sam-
ples, there is a real need to coordinate studies and conduct large
prospective clinical trials assessing for diagnosis, follow-up, or
response to treatment not only HSPs but also other potential bio-
markers simultaneously using quantitative methods. One option
is the design of surface plasmon resonance techniques measur-
ing several proteins in parallel (Seigneuric et al., 2010) as well as
tumor-exosomes and CTCs in biological ﬂuids.
These are new and interesting frontiers worth investigating that
may offer the opportunity to detect cancer early danger signals.
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